However, other key studies by Hermann et al. have identified CD133+/CXCR4+ PDAC cells as possessing an enhanced metastatic capacity in addition to their tumor-initiating capacity when compared to CD133−/CXCR4– populations [63]. The gene discussed is CXCR4; the disease is neoplasm.